An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors. (September 2017)

• Record Type: Journal Article
• Authors: Lo, Chih Hung; Vunnam, Nagamani; Lewis, Andrew K.; Chiu, Ting-Lan; Brummel, Benjamin E.; Schaaf, Tory M.; Grant, Benjamin D.; Bawaskar, Prachi; Thomas, David D.; Sachs, Jonathan N.
• Is Part Of: SLAS discovery. Volume 22:Number 8(2017)
• Page Start: 950
• Page End: 961
• Publication Date: 2017-09
• Subjects: tumor necrosis factor receptor 1 -- pre-ligand assembly domain -- receptor–receptor interaction -- time-resolved FRET -- NF-κB inhibition; Drugs -- Analysis -- Periodicals; Drugs -- Testing -- Periodicals; Biomolecules -- Analysis -- Periodicals; Biomolecules -- Analysis; Drugs -- Analysis; Drugs -- Testing; Drug Evaluation, Preclinical; Molecular Biology -- methods; Periodicals; Periodicals; 615.1
• DOI: 10.1177/2472555217706478
• Languages: English
• ISSNs: 2472-5552

Abstract

Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that binds tumor necrosis factor or lymphotoxin-alpha and plays a critical role in regulating the inflammatory response. Upregulation of these ligands is associated with inflammatory and autoimmune diseases. Current treatments reduce symptoms by sequestering free ligands, but this can cause adverse side effects by unintentionally inhibiting ligand binding to off-target receptors. Hence, there is a need for new small molecules that specifically target the receptors, rather than the ligands. Here, we developed a TNFR1 FRET biosensor expressed in living cells to screen compounds from the NIH Clinical Collection. We used an innovative high-throughput fluorescence lifetime screening platform that has exquisite spatial and temporal resolution to identify two small-molecule compounds, zafirlukast and triclabendazole, that inhibit the TNFR1-induced IκBα degradation and NF-κB activation. Biochemical and computational docking methods were used to show that zafirlukast disrupts the interactions between TNFR1 pre-ligand assembly domain (PLAD), whereas triclabendazole acts allosterically. Importantly, neither compound inhibits ligand binding, proving for the first time that it is possible to inhibit receptor activation by targeting TNF receptor–receptor interactions. This strategy should be generally applicable to other members of the TNFR superfamily, as well as to oligomeric receptors in general.